9月12日15:33,荃信生物-B(02509)大幅上涨5.14%,该股报30.260港元,最高报30.260港元,最低报27.600港元,成交量111.06万股,成交额3196.51万港元。消息面上,公司近日发布公告称,其在研药物QX004N是一款针对白介素23p19亚基(IL23p19)的抑制剂,拟用于治疗银屑病及克罗恩病。近期,该药物已进入III期临床试验,成为公司管线中第四个进入III期...
Source Link9月12日15:33,荃信生物-B(02509)大幅上涨5.14%,该股报30.260港元,最高报30.260港元,最低报27.600港元,成交量111.06万股,成交额3196.51万港元。消息面上,公司近日发布公告称,其在研药物QX004N是一款针对白介素23p19亚基(IL23p19)的抑制剂,拟用于治疗银屑病及克罗恩病。近期,该药物已进入III期临床试验,成为公司管线中第四个进入III期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.